-
Policy Analysis: Shanghai’s 2025 Pharmaceutical Procurement Regulation and Market Implications
•
Shanghai’s Medical Centralized Bidding and Procurement Affairs Management Office has released its January 2025 list of monitored pharmaceutical varieties under the public tendering and price negotiation framework. The policy, outlined in Document No. 104 of 2023, emphasizes transparency, fairness, and price rationality in inter-provincial drug procurement. This regulatory move underscores…
-
SMPA Suspends Indobufen Procurement After Patent Infringement Verdict
•
Shanghai’s Sunshine Medical Procurement All-In-One (SMPA) announced the suspension of procurement for indobufen, manufactured by Hunan Jiudian Pharmaceutical and Zhejiang Tongwu Biomedical, following a patent infringement verdict by the Hangzhou Intellectual Property Office. The decision highlights ongoing disputes over the drug’s patent status in China. BackgroundIndobufen, an isoindolylphenylbutyric acid derivative…
-
Shanghai Procurement Platform Offers Price Cut Leeway to Escape ‘High-Priced Drugs’ Tag
•
Shanghai’s Sunshine Medical Procurement All-in-One (SMPA) platform has announced a significant policy shift regarding non-winning bids in the 9th round of volume-based procurement (VBP). The notification suggests that drugs which did not secure a winning bid and are eligible for online procurement in Shanghai may be exempted from the “high-priced…
-
Hangzhou Singclean Stripped of VBP Status for Artificial Lenses
•
Shanghai’s Sunshine Medical Procurement All-in-One (SMPA) has revealed that Hangzhou Singclean Medical Products Co., Ltd has been stripped of its volume-based procurement (VBP) winning status and blacklisted from further VBP participation. This follows Singclean’s decision to relinquish a tender it had previously won to supply artificial lenses. The notice indicates…
-
China’s NRDL Update: New Drugs Available for Online Procurement
•
Shanghai’s Sunshine Medical Procurement All-in-One (SMPA) drug procurement platform has released a notice stating that drugs newly added to the 2022 edition of the National Reimbursement Drug List (NRDL) are now available for online procurement by hospitals. The 2022 NRDL update, which was completed in mid-January 2023, includes 111 newly…
-
Shanghai Hosts Yangtze River Delta Alliance VBP Tender for 44 Drugs
•
Shanghai’s Sunshine Medical Procurement All-in-One (SMPA) has released a document indicating that the city will host the Yangtze River Delta Alliance volume-based procurement (VBP) tender for 44 drugs on December 13, 2022. The tender involves drugs from Shanghai, Zhejiang, and Anhui provinces. The total procurement amount is estimated at around…
-
Shanghai SMPA Suspends HEC’s Linagliptin Procurement Over Patent Infringement
•
The Shanghai Sunshine Medical Procurement All-in-One (SMPA) platform has revealed that it has suspended the procurement qualifications for HEC Group’s linagliptin (5mg × 7 boxes). HEC’s product is a generic version of German major Boehringer Ingelheim’s (BI) Trajenta. The decision was taken to ensure that intellectual property (IP) rights are…
-
7th National VBP Round Venue Moved to Nanjing from Shanghai
•
In a departure from previous practice, the 7th national volume-based procurement (VBP) round will not take place in Shanghai. According to a notification from the Sunshine Medical Procurement All-in-One (SMPA) platform, the filing address and disclosure location have been changed to Nanjing, Jiangsu Province. Filing DetailsThe filing start time and…
-
China’s Seventh National Volume-based Procurement Round Kicks Off with Revised Rules
•
China’s health authorities have resumed the seventh national volume-based procurement (VBP) round after a pandemic-related delay. The Shanghai Sunshine Medical Procurement All-in-One (SMPA) platform has issued a notification outlining the bidding and procurement rules for 61 drug varieties across 147 specifications. The round will involve nearly 300 manufacturers, with competitive…
